S&P 500   4,508.44 (+0.49%)
DOW   35,376.15 (+0.33%)
QQQ   374.11 (+0.39%)
AAPL   148.55 (+1.36%)
MSFT   308.36 (+0.35%)
FB   339.08 (+1.12%)
GOOGL   2,856.15 (+0.02%)
TSLA   867.68 (-0.28%)
AMZN   3,436.17 (-0.31%)
NVDA   221.33 (-0.40%)
BABA   172.77 (+3.57%)
NIO   39.94 (+0.83%)
CGC   13.40 (+1.52%)
GE   104.36 (+0.23%)
AMD   115.53 (-0.77%)
MU   66.70 (-0.83%)
T   25.36 (+0.12%)
F   15.52 (-0.26%)
ACB   6.96 (+0.58%)
DIS   170.75 (-0.23%)
PFE   41.92 (+1.45%)
BA   216.10 (-0.41%)
AMC   43.02 (-0.02%)
S&P 500   4,508.44 (+0.49%)
DOW   35,376.15 (+0.33%)
QQQ   374.11 (+0.39%)
AAPL   148.55 (+1.36%)
MSFT   308.36 (+0.35%)
FB   339.08 (+1.12%)
GOOGL   2,856.15 (+0.02%)
TSLA   867.68 (-0.28%)
AMZN   3,436.17 (-0.31%)
NVDA   221.33 (-0.40%)
BABA   172.77 (+3.57%)
NIO   39.94 (+0.83%)
CGC   13.40 (+1.52%)
GE   104.36 (+0.23%)
AMD   115.53 (-0.77%)
MU   66.70 (-0.83%)
T   25.36 (+0.12%)
F   15.52 (-0.26%)
ACB   6.96 (+0.58%)
DIS   170.75 (-0.23%)
PFE   41.92 (+1.45%)
BA   216.10 (-0.41%)
AMC   43.02 (-0.02%)
S&P 500   4,508.44 (+0.49%)
DOW   35,376.15 (+0.33%)
QQQ   374.11 (+0.39%)
AAPL   148.55 (+1.36%)
MSFT   308.36 (+0.35%)
FB   339.08 (+1.12%)
GOOGL   2,856.15 (+0.02%)
TSLA   867.68 (-0.28%)
AMZN   3,436.17 (-0.31%)
NVDA   221.33 (-0.40%)
BABA   172.77 (+3.57%)
NIO   39.94 (+0.83%)
CGC   13.40 (+1.52%)
GE   104.36 (+0.23%)
AMD   115.53 (-0.77%)
MU   66.70 (-0.83%)
T   25.36 (+0.12%)
F   15.52 (-0.26%)
ACB   6.96 (+0.58%)
DIS   170.75 (-0.23%)
PFE   41.92 (+1.45%)
BA   216.10 (-0.41%)
AMC   43.02 (-0.02%)
S&P 500   4,508.44 (+0.49%)
DOW   35,376.15 (+0.33%)
QQQ   374.11 (+0.39%)
AAPL   148.55 (+1.36%)
MSFT   308.36 (+0.35%)
FB   339.08 (+1.12%)
GOOGL   2,856.15 (+0.02%)
TSLA   867.68 (-0.28%)
AMZN   3,436.17 (-0.31%)
NVDA   221.33 (-0.40%)
BABA   172.77 (+3.57%)
NIO   39.94 (+0.83%)
CGC   13.40 (+1.52%)
GE   104.36 (+0.23%)
AMD   115.53 (-0.77%)
MU   66.70 (-0.83%)
T   25.36 (+0.12%)
F   15.52 (-0.26%)
ACB   6.96 (+0.58%)
DIS   170.75 (-0.23%)
PFE   41.92 (+1.45%)
BA   216.10 (-0.41%)
AMC   43.02 (-0.02%)
NASDAQ:MBII

Marrone Bio Innovations Stock Forecast, Price & News

$0.90
+0.02 (+2.26 %)
(As of 10/18/2021 04:00 PM ET)
Add
Compare
Today's Range
$0.86
$0.92
50-Day Range
$0.82
$1.48
52-Week Range
$0.77
$2.90
Volume326,729 shs
Average Volume610,679 shs
Market Capitalization$159.36 million
P/E RatioN/A
Dividend YieldN/A
Beta0.28
30 days | 90 days | 365 days | Advanced Chart
Receive MBII News and Ratings via Email

Sign-up to receive the latest news and ratings for Marrone Bio Innovations and its competitors with MarketBeat's FREE daily newsletter.


Marrone Bio Innovations logo

About Marrone Bio Innovations

Marrone Bio Innovations, Inc. engages in the provision of Biological based solutions for agricultural crops, turf protection, seed treatment, plant health and waterway systems. Its products include Grandevo Insecticide, Majestene Nematicide, Regalia Fungicide, Stargus Fungicide, Venerate Insecticide, Amplitude Fungicide, Regalia Rx Plant Health, Zelto Nematicide, Zequanox Molluscicide and Haven. The company was founded by Pamela G. Marrone on June 15, 2006 and is headquartered in Davis, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Agricultural chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:MBII
Employees
145
Year Founded
N/A

Sales & Book Value

Annual Sales
$38.37 million
Book Value
$0.19 per share

Profitability

Net Income
$-20.17 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$159.36 million
Next Earnings Date
11/8/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.84 out of 5 stars

Basic Materials Sector

138th out of 225 stocks

Agricultural Chemicals Industry

10th out of 14 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Marrone Bio Innovations (NASDAQ:MBII) Frequently Asked Questions

Is Marrone Bio Innovations a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marrone Bio Innovations in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Marrone Bio Innovations stock.
View analyst ratings for Marrone Bio Innovations
or view top-rated stocks.

What stocks does MarketBeat like better than Marrone Bio Innovations?

Wall Street analysts have given Marrone Bio Innovations a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Marrone Bio Innovations wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Marrone Bio Innovations?

Marrone Bio Innovations saw a decline in short interest in September. As of September 30th, there was short interest totaling 1,620,000 shares, a decline of 20.2% from the September 15th total of 2,030,000 shares. Based on an average daily volume of 686,500 shares, the days-to-cover ratio is currently 2.4 days. Currently, 1.7% of the company's shares are sold short.
View Marrone Bio Innovations' Short Interest
.

When is Marrone Bio Innovations' next earnings date?

Marrone Bio Innovations is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Marrone Bio Innovations
.

How were Marrone Bio Innovations' earnings last quarter?

Marrone Bio Innovations, Inc. (NASDAQ:MBII) released its quarterly earnings results on Sunday, August, 15th. The basic materials company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.01. The basic materials company had revenue of $12.60 million for the quarter, compared to analysts' expectations of $17.59 million. Marrone Bio Innovations had a negative trailing twelve-month return on equity of 53.18% and a negative net margin of 41.23%.
View Marrone Bio Innovations' earnings history
.

How has Marrone Bio Innovations' stock been impacted by Coronavirus (COVID-19)?

Marrone Bio Innovations' stock was trading at $0.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MBII shares have increased by 5.1% and is now trading at $0.9040.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MBII?

5 equities research analysts have issued 12 month target prices for Marrone Bio Innovations' stock. Their forecasts range from $2.00 to $4.00. On average, they anticipate Marrone Bio Innovations' stock price to reach $2.90 in the next year. This suggests a possible upside of 220.8% from the stock's current price.
View analysts' price targets for Marrone Bio Innovations
or view top-rated stocks among Wall Street analysts.

Who are Marrone Bio Innovations' key executives?

Marrone Bio Innovations' management team includes the following people:
  • Kevin R. Helash, Chief Executive Officer & Director
  • Sue Cheung, Chief Financial Officer
  • Amit Vasavada, Chief Technology Officer, Senior VP-R&D
  • Linda V. Moore, Secretary, Chief Compliance Officer & EVP
  • Keith J. Pitts, Chief Sustainability Officer & Senior VP

What other stocks do shareholders of Marrone Bio Innovations own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marrone Bio Innovations investors own include Ekso Bionics (EKSO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), KushCo (KSHB), Enerplus (ERF), ADMA Biologics (ADMA), Great Panther Mining (GPL), OrganiGram (OGI), 22nd Century Group (XXII) and Aeterna Zentaris (AEZS).

What is Marrone Bio Innovations' stock symbol?

Marrone Bio Innovations trades on the NASDAQ under the ticker symbol "MBII."

How do I buy shares of Marrone Bio Innovations?

Shares of MBII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marrone Bio Innovations' stock price today?

One share of MBII stock can currently be purchased for approximately $0.90.

How much money does Marrone Bio Innovations make?

Marrone Bio Innovations has a market capitalization of $159.36 million and generates $38.37 million in revenue each year. The basic materials company earns $-20.17 million in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does Marrone Bio Innovations have?

Marrone Bio Innovations employs 145 workers across the globe.

What is Marrone Bio Innovations' official website?

The official website for Marrone Bio Innovations is www.marronebioinnovations.com.

Where are Marrone Bio Innovations' headquarters?

Marrone Bio Innovations is headquartered at 1540 Drew Avenue, Davis CA, 95618.

How can I contact Marrone Bio Innovations?

Marrone Bio Innovations' mailing address is 1540 Drew Avenue, Davis CA, 95618. The basic materials company can be reached via phone at (530) 750-2800 or via email at [email protected].


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.